- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00102648
Lonafarnib and Temozolomide in Treating Patients With Glioblastoma Multiforme That Is Recurrent or Did Not Respond to Previous Treatment With Temozolomide
Phase I/Ib Study of Sarasar and Temodar in Patients With Recurrent or Temodar-Refractory Glioblastoma Multiforme
Study Overview
Status
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To determine the maximum tolerated dose Sarasar (SCH66336, lonafarnib) when combined with Temodar (temozolomide) in an alternating week schedule.
II. To describe the toxicities of the Sarasar and Temodar combination treatment using this dosing schedule.
III. To evaluate response as measured by 6-month progression-free survival and objective tumor response.
OUTLINE: This is a dose-escalation study of lonafarnib.
Patients receive temozolomide orally (PO) once daily (QD) on days 1-7 and 15-21 and lonafarnib PO twice daily (BID) on days 8-14 and 22-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- M D Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with histologically proven supratentorial glioblastoma multiforme (GBM) or gliosarcoma
- Patients must have shown unequivocal evidence for tumor recurrence or progression by magnetic resonance imaging (MRI) scan after radiation therapy; the scan done prior to study entry documenting progression will be reviewed by the treating physician to document tumor volume changes to provide a gross assessment of growth rate
- Patients may have had as many as 2 prior chemotherapy regimens for recurrent or progressive tumor; patients must have had prior treatment with Temodar but may not have had prior treatment with farnesyl transferase inhibitors (Sarasar or Zarnestra); patients in phase 1b expansion are required to have received a minimum of two cycles of adjuvant temozolomide (TMZ)
- All patients must sign an informed consent indicating that they are aware of the investigational nature of this study in keeping with the policies of this hospital
- Patients must have shown unequivocal evidence for tumor progression by MRI or computed tomography (CT) scan; a scan should be performed within 14 days prior to registration and on a steroid dose that has been stable or decreasing for at least 5 days; if the steroid dose is increased between the date of imaging and registration a new baseline magnetic resonance (MR)/CT is required; the same type of scan, i.e., MRI or CT must be used throughout the period of protocol treatment for tumor measurement
Patients (pts) having had recent resection of recurrent or progressive tumor are eligible as long as:
- Patients must be status post surgical resection at least 2 weeks prior to study enrollment, have recovered from surgery, have adequate early wound healing and a Karnofsky performance status of > or = 60
- Residual disease following resection of recurrent tumor is not mandated for eligibility into the study; a CT/MRI should be done within 96 hours (hrs) post-op or at least 4 weeks (wks) post-op (within 14 days of registration); if the steroid dose is increased between the scan date and registration, a new baseline MRI/CT is required on a stable steroid dose for 5 days
- Patients must have a Karnofsky performance status of >= 60
- Patients must have recovered from the toxic effects of prior therapy: 4 weeks from prior cytotoxic therapy and/or at least two weeks from vincristine, 6 weeks from nitrosoureas, 3 weeks from procarbazine administration, and 1 week for non-cytotoxic agents, e.g., interferon, tamoxifen, thalidomide, cis-retinoic acid, etc. (radiosensitizer does not count); any questions related to the definition of non-cytotoxic agents should be directed to the study chair
- Absolute neutrophil count (ANC) >= 1,500/mm^3
- Platelet count of >= 100,000/mm^3
- Serum glutamic pyruvate transaminase (SGPT) < 2.5 times normal
- Alkaline phosphatase < 2.5 times normal
- Bilirubin < 1.5 mg
- Blood urea nitrogen (BUN) < 1.5 times institutional normal
- Creatinine < 1.5 times institutional normal
Exclusion Criteria:
- Patients must not be taking primidone, carbamazepine, phenobarbital or phenytoin anticonvulsants; patients changing from these anticonvulsants to other allowable drugs that are not enzyme inducing antiepileptic drugs (EIAEDs) must be off the drugs listed above for at least 72 hours prior the initiation of treatment
- Patients with a history of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix), are ineligible unless in complete remission and off of all therapy for that disease for a minimum of 3 years
Patients must not have:
- Uncontrolled active infection
- Disease that will obscure toxicity or dangerously alter drug metabolism
- Serious intercurrent medical illness
- Prior recurrence with a farnesyl transferase inhibitor
- Oral contraceptives and other hormonal methods (Depo-Provera) of birth control
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (temozolomide and lonafarnib)
Patients receive temozolomide PO QD on days 1-7 and 15-21 and lonafarnib PO BID on days 8-14 and 22-28.
Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
|
Given PO
Other Names:
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Maximum tolerated dose (MTD) of lonafarnib when given with temozolomide, defined as the dose at which fewer than one-third of patients experience dose-limiting toxicity (DLT)
Time Frame: 28 days
|
28 days
|
Tolerability of regimen in patients with disease progression or recurrence during or after recent completion of treatment with temozolomide
Time Frame: Up to 11 years
|
Up to 11 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression free survival (PFS)
Time Frame: 6 months
|
In the historical dataset, the proportion of patients remaining alive and free from progression at 6 months was 15% (95% confidence interval for ranged from 10% to 19%).
We will set p0 to 15% and we will set p1 to 30% (looking for a doubling of the 6-month PFS rate).
Based on these design parameters, a two-stage design would require that at least 4 of the initial 19 patients are without progression at 6 months.
|
6 months
|
Objective response
Time Frame: Up to 11 years
|
Up to 11 years
|
|
Overall survival
Time Frame: Up to 11 years
|
Up to 11 years
|
|
Treatment-related toxicities
Time Frame: Up to 11 years
|
Treatment-related toxicity data will be collected and described.
|
Up to 11 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Vinay Puduvalli, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Disease Attributes
- Astrocytoma
- Glioma
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Brain Neoplasms
- Central Nervous System Neoplasms
- Nervous System Neoplasms
- Glioblastoma
- Recurrence
- Gliosarcoma
- Supratentorial Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Temozolomide
- Lonafarnib
Other Study ID Numbers
- 2004-0424 (Other Identifier: M D Anderson Cancer Center)
- NCI-2012-01311 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- NCI-2010-00417
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Glioblastoma
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); University of California, Los Angeles; Oncoceutics...WithdrawnRecurrent Glioblastoma | Recurrent Gliosarcoma | Recurrent Supratentorial Glioblastoma | Supratentorial GliosarcomaUnited States
-
Massachusetts General HospitalNot yet recruitingGlioblastoma Recurrent, EGFR vIII Mutant | Newly Diagnosed Glioblastoma, EGFRvIII Mutant | Recurrent Glioblastoma, EGFR vIII NegativeUnited States
-
National Cancer Institute (NCI)SuspendedRecurrent Glioblastoma, IDH-Wildtype | MGMT-Methylated Glioblastoma | Recurrent MGMT-Methylated GlioblastomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRecurrent Glioblastoma | Giant Cell Glioblastoma | Recurrent GliosarcomaUnited States
-
University of OklahomaGlaxoSmithKlineTerminatedRecurrent Glioblastoma | Recurrent Glioma | Recurrent Astrocytoma | Recurrent OligodendrogliomaUnited States
-
University of Michigan Rogel Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Glioblastoma | Newly Diagnosed Glioblastoma | Recurrent Gliosarcoma | Recurrent Astrocytoma, Grade IV | Newly Diagnosed Gliosarcoma | Newly Diagnosed Astrocytoma, Grade IVUnited States
-
Center for Neurosciences, TucsonGenentech, Inc.CompletedRecurrent Glioblastoma Multiforme | Recurrent GliosarcomaUnited States
-
Northwestern UniversityBristol-Myers Squibb; Lantheus Medical Imaging; CarTheraRecruitingGlioblastoma | Glioblastoma Multiforme | Gliosarcoma | GBM | Recurrent Glioblastoma | Glioblastoma, IDH-wildtypeUnited States
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Recurrent Glioblastoma | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain | Astrocytoma of Brain | Astrocytoma, MalignantUnited States, Germany, Netherlands, Switzerland, Belgium
-
Jonsson Comprehensive Cancer CenterBristol-Myers Squibb; Northwest Biotherapeutics; Brain Tumor Funders CollaborativeWithdrawnGliosarcoma | Recurrent Glioblastoma | Oligodendroglioma | Small Cell Glioblastoma | Giant Cell GlioblastomaUnited States
Clinical Trials on Temozolomide
-
Guangzhou Medical UniversityUnknownSmall Cell Lung Cancer | Metastatic CarcinomaChina
-
Bradmer Pharmaceuticals Inc.Terminated
-
University of SouthamptonBristol-Myers SquibbRecruitingCancer of Esophagus | Adenocarcinoma - GEJUnited Kingdom
-
Novartis PharmaceuticalsCompletedGlioblastomaAustralia, Spain, Canada, United States
-
Activartis BiotechCompleted
-
Peking Union Medical College HospitalBeijing Tiantan Hospital; Tianjin Medical University General HospitalUnknownMalignant GliomasChina
-
Yunpeng LiuUnknownExtensive Stage Small Cell Lung CancerChina
-
Yong-Kil HongNational Cancer Center, Korea; Samsung Medical Center; Seoul St. Mary's Hospital and other collaboratorsCompletedGlioblastomaKorea, Republic of
-
Medical University of South CarolinaTerminatedGlioma | Astrocytoma | Brain Tumor | Glioblastoma MultiformeUnited States
-
Merck Sharp & Dohme LLCTerminatedBreast Neoplasm | Brain Neoplasm | Second Neoplasm